Modeling bone marrow toxicity using kinase structural motifs and the inhibition profiles of small molecular kinase inhibitors

Toxicological Sciences

Volumn 118, Issue 1, 2010, Pages 266-275

  Olaharski, Andrew J ^a   Bitter, Hans ^a   Gonzaludo, Nina ^b   Kondru, Rama ^c   Goldstein, David M ^c   Zabka, Tanja S ^a   Lin, Henry ^b   Singer, Thomas ^d   Kolaja, Kyle ^a  

^a Translational Research Sciences   (United States)

^b Roche Palo Alto   (United States)

^c Discovery Chemistry   (United States)

^d Non Clinical Safety   (Switzerland)

Author keywords

Bone marrow toxicity; Mathematical modeling; Small molecule kinase inhibitors; Support vector machines

Indexed keywords

ABC TRANSPORTER; AURORA C KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IIA; CYCLIN DEPENDENT KINASE 17; EPHRIN RECEPTOR B1; MITOGEN ACTIVATED PROTEIN KINASE 14; MYOTONIC DYSTROPHY PROTEIN KINASE; P21 ACTIVATED KINASE 7; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE; PROTEIN KINASE CLK1; PROTEIN KINASE CSNK1E; PROTEIN KINASE LCK; PROTEIN KINASE MET; PROTEIN KINASE MKNK2; PROTEIN KINASE MYLK2; PROTEIN KINASE N; PROTEIN KINASE N1; PROTEIN KINASE NEK7; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN KINASE STK10; SMALL MOLECULE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ACCURACY; ALGORITHM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TOXICITY; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; DRUG DESIGN; DRUG INFORMATION; DRUG SAFETY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; GENE CLUSTER; HEMATOPOIETIC CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PROTEIN MOTIF; SUPPORT VECTOR MACHINE; TOXICOLOGICAL PARAMETERS;

ADENOSINE TRIPHOSPHATE; ALGORITHMS; ANIMALS; ARTIFICIAL INTELLIGENCE; BONE MARROW CELLS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEOMICS; ROC CURVE;

EID: 77958491690     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq258     Document Type: Article

References (48)

1. Agosti, V., Karur, V., Sathyanarayana, P., Besmer, P., and Wojchowski, D. M. (2009). A KIT juxtamembrane PY567 -directed pathway provides non- redundant signals for erythroid progenitor cell development and stress erythropoiesis. Exp. Hematol. 37, 159-171.
2. Agrawal, S., Koschmieder, S., Baumer, N., Reddy, N. G., Berdel, W. E., and Serve, H. (2008). Pim2 complements Flt3 wild-type receptor in hematopoi- etic progenitor cell transformation. Leukemia 22, 78-86.
3. Belkina, N. V., Liu, Y., Hao, J. J., Karasuyama, H., and Shaw, S. (2009). LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 106, 4707-4712.
4. Busse, D., Yakes, F. M., Lenferink, A. E., and Arteaga, C. L. (2001). Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance. Semin. Oncol. 28(5 Suppl. 16), 47-55.
5. Chen, J. L., Limnander, A., and Rothman, P. B. (2008). Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 111, 1677-1685.
6. Chen, K., Rund, L. A., Beever, J. E., and Schook, L. B. (2006). Isolation and molecular characterization of the porcine transforming growth factor beta type I receptor (TGFBR1) gene. Gene 384, 62-72.
7. Cohen, A. M., Grinblat, B., Bessler, H., Kristt, D., Kremer, A., Schwartz, A., Halperin, M., Shalom, S., Merkel, D., and Don, J. (2004). Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk. Lymphoma 45, 951-955.
8. Cortes, J., Kim, D. W., Raffoux, E., Martinelli, G., Ritchie, E., Roy, L., Coutre, S., Corm, S., Hamerschlak, N., Tang, J. L., et al. (2008). Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22, 2176-2183.
9. Druker, B. J., Guilhot, F., O'Brein, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417.
10. Everitt, B., Landau, S., and Leese, M. (2001). In Cluster Analysis, 4th ed. Arnold, London.
11. Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005). A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336.
12. Fierro, F., Illmer, T., Jing, D., Schleyer, E., Ehningler, G., Boxberger, S., and Bornhauser, M. (2007). Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif. 40, 355-366.
13. Geest, C. R., and Coffer, P. J. (2009). MAPK signaling pathways in the regulation of hematopoiesis. J. Leukoc. Biol. 86, 237-250.
14. Goldstein, D. M., Alfredson, T., Bertrand, J., Brownder, M. F., Clifford, K., Dalymple, S. A., Dunn, J., Freire-Moar, J., Harris, S., Labadie, S. S., et al. (2006). Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3- (2,3-dihydroxypropoxy)ph enyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. J. Med. Chem. 49, 1562-1575.
15. Gupta, P., Friberg, L. E., Karlsson, M. O., Krishnaswami, S., and French, J. (2009). A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J. Clin. Pharmacol. 50, 679-687.
16. Huang, J., Zhang, Y., Bersenv, A., O'Brein, W. T., Tong, W., Emerson, S. G., and Klein, P. S. (2009). Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. J. Clin. Invest. 119, 3519-3529.
17. Ikehara, S. (1996). Role of hepatocyte growth factor in hemopoiesis. Leuk. Lymphoma 23, 297-303.
18. Kaminski, W. E., Lindahl, P., Lin, L. N., Broudy, V. C., Crosby, J. R., Hellstrom, M., Swolin, B., Bower-Pope, D. F., Martin, P. J., Ross, R., et al. (2001). Basis of hematopoietic defects in platelet-derived growth factor (PDGF)-B and PDGF beta-receptor null mice. Blood 97, 1990-1998.
19. Kaufman, L., and Rousseeuw, P. (1990). Finding Groups in Data: An Introduction to Cluster Analysis. Wiley, New York.
20. Kim, S., Lee, K., and Rhee, K. (2007). NEK7 is a centrosomal kinase critical for microtubule nucleation. Biochem. Biophys. Res. Commun. 360, 56-62.
21. Kremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishaswami, S., Burgos-Vargas, R., Wilkinson, B., Zerbini, C. A., and Zwillich, S. H. (2009). The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60, 1895-1905.
22. Kuramochi, S., Moriguichi, T., Kuida, K., Endo, J., Semba, K., Nishida, E., and Karasuyama, H. (1997). LOK is a novel mouse STE20-like protein kinase that is expressed predominantly in lymphocytes. J. Biol. Chem. 272, 22679-22684.
23. Lai, L., Zeff, R. A., and Goldschneider, I. (2006). A recombinant single-chain IL-7/HGFbeta hybrid cytokine induces juxtacrine interactions of the IL-7 and HGF (c-Met) receptors and stimulates the proliferation of CFU-S12, CLPs, and pre-pro-B cells. Blood 107, 1776-1784.
24. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002). The protein kinase complement of the human genome. Science 298, 1912-1934.
25. Morishita, D., Katayama, R., Sekimizu, K., Tsuruo, T., and Fujita, N. (2008). Pim kinases promote cell cycle progression by phosphorylating and down- regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 68, 5076-5085.
26. Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006). Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524.
27. Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Yamamoto, N., Takeda, K., Swailand, H., Nakatani, I., Hirose, M., Dong, R. P., et al. (2003). Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol. 14, 922-930.
28. Navas, T. A., Nguyen, A. N., Hideshima, T., Reddy, M., Ma, J. Y., Haghnazari, E., Henson, M., Stebbins, E. G., Kerr, I., et al. (2006). Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 108, 4170-4177.
29. Navas, T., Zhou, L., Estes, M., Hagnazari, E., Nguyen, A. N., Mo, Y., Pahanish, P., Mohindru, M., Cao, T., Higgins, L. S., Platanias, L. C., et al. (2008). Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk. Lymphoma 49, 1963-1975.
30. Olaharski, A. J., Gonzaludo, N., Bitter, H., Goldstein, D., Kirchner, S., Uppal, H., and Kolaja, K. (2009a). Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors. PLoS Comput. Biol. 5, e1000446.
31. Olaharski, A. J., Uppal, H., Cooper, M., Platz, S., Zabka, T. S., and Kolaja, K. (2009b). In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates. Toxicol. Lett. 188, 98-103.
32. O'Regan, L., and Fry, A. M. (2009). The Nek6 and Nek7 protein kinases are required for robust mitotic spindle formation and cytokinesis. Mol. Cell. Biol. 29, 3975-3990.
33. Santos, F. P., Kantarjian, H. M., Jain, N., Manshouri, T., Thomas, D. A., Garcia-Manero, G., Kennedy, D., Estrov, Z., Cortes, J., and Verstovsek, S. (2009). Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115, 1131-1136.
34. Sasai, K., Katayama, H., Stenoien, D. L., Fujii, S., Honda, R., Kimura, M., Okano, Y., Tatsuka, M., Suzuki, F., Nigg, E. A., et al. (2004). Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil. Cytoskeleton 59, 249-263.
35. Sillibourne, J. E., Milne, D. M., Takahashi, M., Ono, Y., and Meek, D. W. (2002). Centrosomal anchoring of the protein kinase CK1delta mediated by attachment to the large, coiled-coil scaffolding protein CG-NAP/AKAP450. J. Mol. Biol. 322, 785-797.
36. Skvara, H., Dawid, M., Kleyn, E., Wolff, B., Meingassner, J. G., Knight, H., Dumortier, T., Kopp, T., Fallahi, N., Stary, G., et al. (2008). The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J. Clin. Invest. 118, 3151-3159.
37. Tewari, K., Walent, J., Svaren, J., Zamoyska, R., and Suresh, M. (2006). Differential requirement for Lck during primary and memory CD8{thorn} T cell responses. Proc. Natl. Acad. Sci. U.S.A. 103, 16388-16393.
38. Thomas, S. M., and Brugge, J. S. (1997). Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13, 513-609.
39. Tiedemann, R. E., Zhu, Y. X., Schmidt, J., Yin, H., Shi, C. X., Que, Q., Basu, G., Azorsa, D., Perkins, L. M., Braggio, E., et al. (2009). Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid restricted kinase, GRK6. Blood 115, 1594-1604.
40. Tokunaga, A., Oya, T., Ishii, Y., Motomura, H., Nakamura, C., Ishizawa, S., Fujimori, T., Nabeshima, Y., Umezawa, A., Kanamori, M., et al. (2008). PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. J. Bone Miner. Res. 23, 1519-1528.
41. Utz, A. C., Hirner, H., Blatz, A., Hillenbrand, A., Schmidt, B., Deppert, W., Henne-Bruns, D., Fischer, D., Thal, D. R., Leihauser, F., and Knippschild, U. (2010). Analysis of cell type-specific expression of CK1 epsilon in various tissues of young adult BALB/c Mice and in mammary tumors of SV40 T-Ag-transgenic mice. J. Histochem. Cytochem. 58, 1-15.
42. Vieth, M., Sutherland, J. J., Robertson, D. H., and Campbell, R. M. (2005). Kinomics: characterizing the therapeutically validated kinase space. Drug Discov. Today 10, 839-846.
43. Weimar, I. S., Voermans, C., Bourhis, J. H., Miranda, N., van den Berk, P. C., Nakamura, T., de Gast, G. C., and Gerritsen, W. R. (1998). Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp. Hematol. 26, 885-894.
44. Weisel, K. C., Yildirim, S., Schweikle, E., Kanz, L., and Mohle, R. (2009). Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells. Ann. Hematol. 88, 203-211.
45. Xie, S. H., Li, J. Q., Chen, Y. S., Gao, P., Zhang, H., and Li, Z. Y. (2009). Molecular cloning, expression, and chromosomal mapping of the porcine CDC-2-like kinase 1 (CLK1) gene. Biochem. Genet. 47, 266-275.
46. Yissachar, N., Salem, H., Tennenbaum, T., and Motro, B. (2006). Nek7 kinase is enriched at the centrosome, and is required for proper spindle assembly and mitotic progression. FEBS Lett. 580, 6489-6495.
47. Zayzafoon, M., Fulzele, K., and McDonald, J. M. (2005). Calmodulin and calmodulin-dependent kinase IIalpha regulate osteoblast differentiation by controlling c-fos expression. J. Biol. Chem. 280, 7049-7059.
48. Zhou, L., Opalinska, J., and Verma, A. (2007). p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure. Cell cycle 6, 534-537.